Experimental Research Photodynamic Effects in Perifocal, Oedematous Brain Tissue

Summary.Summary. Background: Photodynamic therapy (PDT) has been under discussion as additional treatment option for malignant gliomas. However, damage not only to tumour tissue but also to normal brain has been demonstrated. The mechanisms of this unwanted side effect have not yet been clearly identified. Spreading of photosensitiser with oedema after disruption of the blood-brain-barrier and potential sensitisation of normal tissue has been found previously. The present study investigates the time- and dose-dependency of normal tissue damage to photodynamic therapy using Photofrin II® after disruption of the blood-brain-barrier. Methods: Male wistar rats anaesthetised with chloral hydrate were subjected to focal, cerebral cold lesions. Simultaneously, Photofrin II® (PFII) was injected (2,5 or 5 mg/kg b.w.). Laser irradiation (630 nm) was performed after 4 h, 12 h and 24 h with varying light doses. Control groups were subjected to focal cold lesion alone, cold lesion with laser irradiation, PFII followed by laser irradiation, or laser irradiation alone (n=6 all groups). 24 h later, brains were removed for assessment of necrosis in coronal sections. Findings: Light dose had a significant impact on the extent of necrosis. Compared to control animals (lesion only: 0.84±0.2 mm2; lesion and irradiation alone: 0.7±0.3 mm2), the area of necrosis was increased to 2.8±0.5 (50 J/cm2), 3.5±1,1 (100 J/cm2) and 4.3±0.7 mm2 (200 J/cm2, 5 mg/kg b.w.; p<0.01). This effect was time-dependent. Maximal necrosis (6.3±1,6 mm2) was observed when brains were irradiated 12 h after PFII injection, with less necrosis occurring at 24 h (2.8±0.4 mm2, p<0.01). Reducing sensitiser dose to 2.5 mg/kg b.w. resulted in a reduction of necrosis (2.09±0.2 mm2, p<0.05). Interpretations: Damage to oedematous tissue after photodynamic therapy using i.v. PFII and laser light at 630 nm depends on laser dose, sensitiser dose and the time point of laser irradiation. The time point of PDT should be considered to prevent unwanted tissue reactions. In the clinical setting however, defined damage to peritumoural tissue may be advantageous. This should be achievable by optimised timing and dosage of photodynamic therapy.

[1]  Andrew H. Kaye,et al.  Photodynamic Therapy of Cerebral Tumors , 1991 .

[2]  D. Noske,et al.  Photodynamic therapy of malignant glioma A review of literature , 1991, Clinical Neurology and Neurosurgery.

[3]  B W Henderson,et al.  Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction. , 1989, Ciba Foundation symposium.

[4]  J. Moan,et al.  Tumor-localizing and photosensitizing properties of the main components of hematoporphyrin derivative. , 1984, Cancer research.

[5]  B. Fisher,et al.  Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. , 1992, International journal of radiation oncology, biology, physics.

[6]  L. O. Svaasand,et al.  OPTICAL PENETRATION IN HUMAN INTRACRANIAL TUMORS , 1985, Photochemistry and photobiology.

[7]  A H Kaye,et al.  Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M Chopp,et al.  The Effect of Hypothermia and Hyperthermia on Photodynamic Therapy of Normal Brain: 141 , 1995, Neurosurgery.

[9]  H. Reulen,et al.  Clearance of edema fluid into cerebrospinal fluid. A mechanism for resolution of vasogenic brain edema. , 1978, Journal of neurosurgery.

[10]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[11]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[12]  B. Henderson,et al.  SITES OF PHOTODAMAGE in vivo and in vitro BY A CATIONIC PORPHYRIN , 1995, Photochemistry and photobiology.

[13]  P. Wen,et al.  Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. , 1998, International journal of radiation oncology, biology, physics.

[14]  K. Maier-Hauff,et al.  Release of glutamate and of free fatty acids in vasogenic brain edema. , 1989, Journal of neurosurgery.

[15]  C. Tengvar.  Extensive intraneuronal spread of horseradish peroxidase from a focus of vasogenic edema into remote areas of central nervous system , 1986, Acta Neuropathologica.

[16]  A H Kaye,et al.  Selective uptake of hematoporphyrin derivative into human cerebral glioma. , 1990, Neurosurgery.

[17]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[18]  T. Mang,et al.  Dihematoporphyrin ether clearance in primate bladders. , 1986, The Journal of urology.

[19]  B. Wilson,et al.  Photodynamic therapy for recurrent supratentorial gliomas. , 1995, Seminars in surgical oncology.

[20]  Walter Stummer,et al.  Kinetics of Photofrin II in perifocal brain edema. , 1993, Neurosurgery.

[21]  A H Kaye,et al.  Photoradiation therapy and its potential in the management of neurological tumors. , 1988, Journal of neurosurgery.

[22]  C Plangger,et al.  Photodynamic treatment of malignant brain tumors. , 1990, Wiener klinische Wochenschrift.

[23]  A. D. Hoyes,et al.  Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. , 1986, British Journal of Cancer.

[24]  D. Kondziolka,et al.  Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. , 1999, Neurosurgery.

[25]  H. Wiśniewski,et al.  Dynamics of Cold Injury Edema , 1967 .

[26]  J. Moore.  Porphyrin Localisation and Treatment of Tumors , 1985 .

[27]  B. Wilson,et al.  Light propagation in animal tissues in the wavelength range 375-825 nanometers. , 1984, Progress in clinical and biological research.

[28]  M. Edwards,et al.  Effect of hematoporphyrin derivative photoradiation therapy on survival in the rat 9L gliosarcoma brain-tumor model. , 1985, Journal of neurosurgery.

[29]  B. Wilson,et al.  An update on the penetration depth of 630 nm light in normal and malignant human brain tissue in vivo. , 1986, Physics in medicine and biology.

[30]  S. Brem,et al.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.

[31]  T J Dougherty,et al.  The structure of the active component of hematoporphyrin derivative. , 1984, Progress in clinical and biological research.

[32]  S. Stylli,et al.  Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Kaye,et al.  Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Sandler,et al.  Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. , 1991, Journal of neurosurgery.

[35]  M Chopp,et al.  Photoactivated Photofrin II: Astrocytic Swelling Precedes Endothelial Injury in Rat Brain , 1992, Journal of neuropathology and experimental neurology.

[36]  S. K. Powers,et al.  Toxicity of photodynamic therapy with photofrin in the normal rat brain , 1994, Lasers in surgery and medicine.

[37]  J. Spikes.  The Role of the Anatomy, Physiology and Biochemistry of Tumors in the Selective Retention of Sensitizers and the Mechanisms of Photosensitized Tumor Destruction , 1988 .

[38]  Harry T. Whelan,et al.  Preclinical Evaluation of Benzoporphyrin Derivative Combined with a Light-Emitting Diode Array for Photodynamic Therapy of Brain Tumors , 1999, Pediatric Neurosurgery.

[39]  K. Sartor,et al.  Early Postoperative Magnetic Resonance Imaging after Resection of Malignant Glioma: Objective Evaluation of Residual Tumor and Its Influence on Regrowth and Prognosis , 1995 .

[40]  W. Stummer,et al.  Kinetics of Photofrin II in perifocal brain edema. , 1993, Neurosurgery.

[41]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[42]  A. Kaye,et al.  Photoradiation therapy causing selective tumor kill in a rat glioma model. , 1987, Neurosurgery.

[43]  L. Lilge,et al.  Photodynamic Therapy of 9L Gliosarcoma with Liposome‐Delivered Photofrin , 1997, Photochemistry and photobiology.

[44]  Satish Krishnamurthy,et al.  Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors , 2000 .

[45]  A. Kaye.  Photoradiation therapy of brain tumours. , 1989, Ciba Foundation symposium.

[46]  M Chopp,et al.  Sensitivity of 9L gliosarcomas to photodynamic therapy. , 1996, Radiation research.

[47]  D. Kessel.  Components of hematoporphyrin derivatives and their tumor-localizing capacity. , 1982, Cancer research.

[48]  W. Kamphorst,et al.  Damage to Tumour and Brain by Interstitial Photodynamic Therapy in the 9L Rat Tumour Model Comparing Intravenous and Intratumoral Administration of the Photosensitiser , 1998, Acta Neurochirurgica.

[49]  F. Hochberg,et al.  Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. , 1988, Neurosurgery.